Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK-155 in Adolescent Postsurgical Acute Pain
NCT02767349Phase 1Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Apr 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNK-155 in acute pain, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Time to reach steady state at 12 hours, Area under the curve at 12 hours and 3 more. Planned start Jan 2016; status: withdrawn.
02
Drugs
MNK-155
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT02767349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767349.